Browsing Category

Production to Prescription Podcast

14 posts

DCAT Value Chain Insights’ original podcast, Production to Prescription, featuring thought leaders with expert views on the major happenings impacting the global bio/pharmaceutical manufacturing value chain and industry performance.

Keep pace with a changing marketplace and hear from industry experts on the issues and trends that need to be on your radar.

For the 2026 podcast schedule click here. See below for the latest episode or get through:

  • Apple Podcast
  • Spotify Podcast

CDMO Outlook: Small Molecules—What Lies Ahead?
By

By
Sponsored by Vetter As the industry reaches the mid-point in 2026, how are CDMOs of small-molecule drugs faring? The larger scale CDMOs with late-phase and/or commercial-scale capabilities are faring well…

A CDMO Roundtable: The Making of a Molecule: Peptide Synthesis
By

By
The blockbuster success of the GLP-1 agonists and related drugs has renewed interest in peptide-based drugs, but how is the manufacturing technology evolving? In a CDMO roundtable, industry experts share…

What Tops the Industry’s Sustainability Agenda for 2026?
By

By
As bio/pharma companies and their suppliers set and implement their sustainability strategies, what issues top the industry’s sustainability agenda? Decarbonizing, standardized reporting of value-chain emissions, and coalescing talent and technology…

2026 Outlook: CDMO Market for Injectables
By

By
Sponsored by Lonza AG In taking a 360-degree view of the CDMO market for injectables, what are the key developments from 2025 that continue to loom large in 2026? Ian…

2026: Drugs To Watch: The Year Ahead
By

By
Which bio/pharmaceuticals, slated to be launched or approved in 2026, may be potential blockbusters or are raising the innovation bar to new heights? Matthew Arnold, Principal Analyst and Content Strategist,…

2025: The Bio/Pharma Industry’s Year in Review
By

By
Without question, evolving US tariff and trade policy was the story of the year, and how such policy will be implemented looms large. At the same time, the normal course…

What’s Trending: ADCs: Pipelines, Products & CDMO Growth 
By

By
Sponsored by Lonza AG Antibody drug conjugates (ADCs) are a niche but growing segment in the global bio/pharmaceutical industry—both on pipeline and market basis and in the CDMO sector. What are…

Drug Launches & Approvals in 2025: The Blockbuster Contenders
By

By
Which bio/pharmaceuticals, launched or approved thus far in 2025, may be potential blockbusters (defined as drugs with sales of $1 billion or more) in the mid term, and what upcoming launches or approvals and trends should be on the industry’s radar? Matthew Arnold, Principal…

CDMOs-Injectables: Tariff Impact: Are Capacity Shifts in the Making?
By

By
Sponsored by Vetter Pharma International GmbH What will be the impact of US tariffs on CDMOs of injectables and on the decision-making of pharma companies on in-sourced/outsourced activity overall and…

Headwinds or Tailwinds: Will the Biotech Sector Rebound in 2025? 
By

By
Biotech companies are an important source for innovation and product development for larger companies and are an important customer base of CDMOs/CMOs. Capital flow in the biotech sector, an important…